NELSEN ROBERT 4

What Happened

• Robert Nelsen, listed as a 10% owner of Sana Biotechnology (SANA), was granted a derivative award covering 90,000 shares on June 4, 2026. The reported acquisition price is $0.00, indicating an equity award/option grant rather than an open-market purchase or sale. This was an award (not a sale), so it is not an immediate bullish or bearish liquidity signal.

Key Details

• Transaction date: 2026-06-04; filing date: 2026-06-05 (timely).
• Transaction type: Grant/Award of a derivative security (code A); reported price $0.00.
• Shares/units granted: 90,000 (derivative/option-style award).
• Vesting/exercise terms (per footnote): The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to Sana’s 2027 annual meeting, provided Robert Nelsen remains in continuous service through that date.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Exhibits: Ex. 24 (Power of Attorney) included in the filing.

Context

• This is a derivative award (option-style grant) that does not represent immediate ownership of common shares until vested and exercised. No shares were sold or exercised in this filing. As a 10% owner, Nelsen’s transactions can reflect founder/large-holder compensation or retention plans rather than routine open-market investing; such awards are common and do not by themselves indicate intent to buy or sell stock.